Inhibitors targeting the PD‐1/PD‐L1 and PD‐L2 pathways have emerged as effective treatments for specific cancer types,55 suggesting that combining EHH with immunotherapy could potentiate anti‐tumour efficacy. This evidence concerns the gene PDCD1LG2 and neoplasm.